Find your next paid study

Washington University School of MedicineNCT02476786

Observational

Implementation of the American College of Surgeons Geriatric Surgery Verification Program at the James Cancer Hospital

This study examines how the American College of Surgeons Geriatric Surgery Verification Program, also called the ACS GSV Program, is implemented at the James C…

Breast CarcinomaMalignant Digestive System NeoplasmMalignant Female Reproductive System Neoplasm+9 more

Ohio State University Comprehensive Cancer CenterNCT07606287

Phase 2

DAREON™-5: An Open-label, Multi-center Phase II Dose Selection Trial of Intravenous BI 764532, a DLL3-targeting T Cell Engager, in Patients With Relapsed/Refractory Extensive-stage Small Cell Lung Cancer and in Patients With Other Relapsed/Refractory Neuroendocrine Carcinomas

This study is open to adults with small cell lung cancer and other neuroendocrine tumours. The study is in people with advanced cancer for whom previous treatm…

Small Cell Lung CarcinomaNeuroendocrine NeoplasmsExtra-pulmonary Neuroendocrine Carcinoma

Boehringer IngelheimNCT05882058

~$10 – $7,500

Colorectal NeoplasmsCarcinoma, Non-Small-Cell LungStomach Neoplasms+3 more

An Open-label Phase 1 Study to Investigate PF-08046050 (SGN-CEACAM5C) in Adults With Advanced Solid Tumors

This clinical trial is studying advanced solid tumors. Solid tumors are cancers that start in a part of your body like your lungs or liver instead of your bloo…

Seagen, a wholly owned subsidiary of PfizerNCT06131840

Phase 3

An Open-label Randomized Phase 3 Study of Tucatinib in Combination With Trastuzumab and mFOLFOX6 Versus mFOLFOX6 Given With or Without Either Cetuximab or Bevacizumab as First-line Treatment for Subjects With HER2+ Metastatic Colorectal Cancer

This study is being done to find out if tucatinib with other cancer drugs works better than standard of care to treat participants with HER2 positive colorecta…

Colorectal Neoplasms

Seagen, a wholly owned subsidiary of PfizerNCT05253651

Carcinoma, Non-Small-Cell LungSquamous Cell Carcinoma of the Head and NeckEsophageal Squamous Cell Carcinoma+5 more

A Phase 1 Study of PF-08046054/SGN-PDL1V in Advanced Solid Tumors

This study will test the safety of a drug called PF-08046054/SGN-PDL1V alone and with pembrolizumab in participants with solid tumors. It will also study the s…

Seagen, a wholly owned subsidiary of PfizerNCT05208762

Myeloproliferative Neoplasms

A Phase 1, Open-Label, Multicenter Study of INCA036978 in Participants With Myeloproliferative Neoplasms

This study will be conducted to determine the safety, tolerability, dose-limiting toxicity (DLT)s, and maximum tolerated dose (MTD) and/or recommended dose for…

Incyte CorporationNCT07441694

Real-World Characteristics, Treatment Patterns, and Clinical Outcomes in Contemporary Patients With Metastatic Castration-Resistant Prostate Cancer in the PRECISION Data Platform

The aim of this study is to assess treatment patterns, clinical outcomes, and patient characteristics among adults with metastatic castration-resistant prostat…

Prostatic Neoplasms, Castration-Resistant

Novartis PharmaceuticalsNCT07677254

~$10 – $1,050

Phase 2

An Open-label, Global, Multi-Arm Study to Evaluate the Efficacy and Safety of Relacorilant in Combination With Different Treatment Regimens in Patients With Gynecological Cancers (BELLA)

This is a Phase 2, open-label, global, multi-arm study to evaluate efficacy and safety of relacorilant in combination with other treatments in patients with gy…

Ovarian CancerFallopian Tube CancerPeritoneal Neoplasms+1 more

Corcept TherapeuticsNCT06906341

Real-World Characteristics, Treatment Patterns, and Outcomes Among Adults With mCRPC Previously Treated With an Androgen Receptor Pathway Inhibitor, Taxane-Based Chemotherapy, and Lutetium-177 Vipivotide Tetraxetan

The aim of this study is to assess treatment patterns, characteristics, and clinical outcomes among adults with metastatic castration-resistant prostate cancer…

Prostatic Neoplasms, Castration-Resistant

Novartis PharmaceuticalsNCT07677267

~$10 – $1,050

Gastrointestinal NeoplasmsGenitourinary CancerThoracic Cancer+2 more

Assessment of Drug-Drug Interactions Between Immune Checkpoint Inhibitors and Cytochrome P450 Substrates: Immune Checkpoint Inhibitor (ICI)-Drug-Drug Interaction (DDI) Study

Immune checkpoint inhibitors (ICIs) (also called "immunotherapy") are an effective family of anti-cancer drugs, but they can cause serious side effects. Some e…

Indiana UniversityNCT07389525

Observational

Exercise for Tumor Suppressive Impact in Men With Prostate Cancer at High-Risk of Progression on Active Surveillance: The REMOVE Trial

The purpose of this study is to determine whether a 12-week, home-based, virtually supervised exercise program will slow cancer progression of prostate cancer …

Prostate CancerProstatic Neoplasms